Organon (OGN) | Stock Overview & Key Data
Organon Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $39.47 on February 28, 2022
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Organon
OGN
|
2.24B Mid-cap | -0.15% | 0.98% | 86.23% | 78.77% | 84.94% | 44.69% | -32.49% | -60.94% | -59.88% | -59.88% | -59.88% |
|
Eli Lilly and
LLY
|
821.31B Mega-cap | -0.01% | 9.99% | 4.58% | 1.77% | -1.46% | 49.80% | 149.81% | 446.98% | 1,370.98% | 2,882.46% | 2,023.77% |
| 555.84B Mega-cap | -3.15% | -0.57% | -10.32% | 8.52% | 7.51% | 45.18% | 43.55% | 35.77% | 96.35% | 240.94% | 270.97% | |
|
Medicus Pharma
MDPLD
|
N/A | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | N/A | N/A | N/A | N/A | N/A | N/A |
|
AbbVie
ABBV
|
351.47B Mega-cap | 1.07% | 3.48% | -8.05% | -4.00% | -6.07% | 16.98% | 59.07% | 93.77% | 234.95% | 559.76% | 559.76% |
|
Merck & Co
MRK
|
283.10B Mega-cap | -3.39% | 2.25% | -4.74% | 14.48% | 8.65% | 54.50% | 5.51% | 60.19% | 119.65% | 247.54% | 266.76% |
Ownership & Short Interest
Calculate Your Organon Investment Returns
Long-Term Investment Performance Analysis
Organon stock price in May 2021 was $33.25, A $1,000.00 lump sum investment in Organon made 5 years ago would be worth approximately $403.01 today, representing a negative return of -59.70%. This translates to an annualized return (CAGR) of -16.43%.
5 Years Investment Scenario (May 2021 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is OGN's 52-week high and low?
- In the last 52 weeks, Organon reached a high of $13.48 (on May 20, 2026) and a low of $5.69 (on March 30, 2026).
- What is the market cap and P/E ratio for OGN?
- Curious about Organon's size and valuation? Its market capitalization stands at 2.24B. When it comes to valuation, the P/E ratio (trailing twelve months) is 11.94, and the forward P/E (looking ahead) is 2.33.
- Does OGN pay dividends? If so, what's the yield?
- Yes, Organon is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.10%, and the company has paid an average of $0.77 per share annually over the past 3 years.
- Who are Organon's main competitors or similar companies to consider before investing?
When looking at Organon, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY821.31B Healthcare Drug Manufacturers - General 49.80% 149.81% Johnson & Johnson
JNJ555.84B Healthcare Drug Manufacturers - General 45.18% 43.55% Medicus Pharma
MDPLDN/A Healthcare Drug Manufacturers - General N/A N/A AbbVie
ABBV351.47B Healthcare Drug Manufacturers - General 16.98% 59.07% Merck & Co
MRK283.10B Healthcare Drug Manufacturers - General 54.50% 5.51% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Organon & Co.? (e.g., ROE, Debt/Equity)
- To get a sense of Organon's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 30.56%, the Debt to Equity ratio from the most recent quarter is 1,170.21, and its Gross Profit Margin stands at 49.17%.
- What is the recent revenue and earnings growth for OGN?
- Looking at Organon's growth, its revenue over the trailing twelve months (TTM) was $6B. Compared to the same quarter last year (YoY), quarterly revenue grew by -5.30%, and quarterly earnings saw a YoY growth of -5.34%.
- How much of OGN stock is held by insiders and institutions?
- Wondering who owns Organon stock? Company insiders (like executives and directors) hold about 0.33% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 77.57%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.